Ampio Pharmaceuticals, Inc. (AMPE)
Chart Events
Performance Outlook
| Previous Close | 1.6900 |
| Open | 1.8300 |
| Bid | 1.7400 x 1100 |
| Ask | 1.7600 x 900 |
| Day's Range | 1.6320 - 1.8300 |
| 52 Week Range | 0.3100 - 2.9800 |
| Volume | 1,834,485 |
| Avg. Volume | 7,544,501 |
| Market Cap | 316.444M |
| Beta (5Y Monthly) | 1.75 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.1070 |
| Earnings Date | Mar 03, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value
Related Research
- PR Newswire
Ampio Pharmaceuticals, Inc. to Report Annual 2020 Financial Results and Provide Corporate Business Update
Ampio Pharmaceuticals (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, today announced it will host a conference call to discuss the financial results for the year ended December 31, 2020 and provide a corporate business update on Wednesday, March 3, 2021 at 4:30pm EST/ 1:30pm PST.
- PR Newswire
Ampio Brings New Hospitals Online in Trial for Inhalation Treatment of COVID-19 with Ampion
Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, today announced the addition of two new study sites to further the expansion of its ongoing U.S. Phase I clinical trial for inhalation treatment of COVID-19 with Ampion ("AP-014"). Principal Investigator Luciano Lemos-Filho, M.D., in Pulmonary and Critical Care and Medical Center Intensive Care Unit Director at Swedish Hospital in Denver, CO, and Principal Investigator David King, M.D., Medical Director at Bozeman Health Clinical Research in Bozeman, MT, bring additional experience to the study and will accelerate the enrollment of patients in the trial.
- PR Newswire
Ampio Pharmaceuticals, Inc. to Present at Upcoming Investor Conference
Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, announced that the Company will present at The Microcap Rodeo Winter Wonderland Conference on February 17, 2021 at 2:30pm EST. This conference is virtual.
